Last reviewed 2026-05-27 · How we verify

Radiosynoviorthesis

Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Phase 3 active Small molecule ✓ Verified May 2026

Radiosynoviorthesis is a Small molecule drug developed by Centre de recherche du Centre hospitalier universitaire de Sherbrooke. It is currently in Phase 3 development. Also known as: Yttrium-90 colloid suspension for local injection.

Radiosynoviorthesis is a minimally invasive procedure that involves the intra-articular injection of radioactive isotopes to treat joint inflammation, particularly synovitis associated with osteoarthritis. This treatment is used to manage joint inflammation, specifically targeting the inflamed synovial membrane.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Radiosynoviorthesis
Also known as	Yttrium-90 colloid suspension for local injection
Sponsor	Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Multicentre Canadian Study to Measure the Safety and Efficacy of Radiosynoviorthesis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Radiosynoviorthesis CI brief — competitive landscape report
Radiosynoviorthesis updates RSS · CI watch RSS
Centre de recherche du Centre hospitalier universitaire de Sherbrooke portfolio CI

Frequently asked questions about Radiosynoviorthesis

What is Radiosynoviorthesis?

Radiosynoviorthesis is a Small molecule drug developed by Centre de recherche du Centre hospitalier universitaire de Sherbrooke.

Who makes Radiosynoviorthesis?

Radiosynoviorthesis is developed by Centre de recherche du Centre hospitalier universitaire de Sherbrooke (see full Centre de recherche du Centre hospitalier universitaire de Sherbrooke pipeline at /company/centre-de-recherche-du-centre-hospitalier-universitaire-de-sherbrooke).

Is Radiosynoviorthesis also known as anything else?

Radiosynoviorthesis is also known as Yttrium-90 colloid suspension for local injection.

What development phase is Radiosynoviorthesis in?

Radiosynoviorthesis is in Phase 3.

Manufacturer: Centre de recherche du Centre hospitalier universitaire de Sherbrooke — full pipeline
Therapeutic area: All drugs in Other
Also known as: Yttrium-90 colloid suspension for local injection

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing